Abstract 19P
Background
County-level hospitals, as the "gatekeepers" for rural cancer patients (pts) in the hierarchical diagnosis and treatment system (HDTS) in China, shoulder significant responsibilities in facilitating cancer treatment and patient referrals. Here, we report the referral data from the CHASE001 trial (NCT05544123).
Methods
CHASE001, a prospective, non-interventional multicenter study exploring real-world treatment and referral practices among pts in Chinese county-level hospitals with HER2+ or HR+/HER2- breast cancer (BC) is ongoing since Sep. 2022. The primary endpoint is to describe the treatment patterns. A key secondary endpoint is referral behavior. Descriptive statistics were utilized to analyze the referral data.
Results
At data cutoff (May 17, 2023), 1436 BC pts were included from 26 county-level hospitals in China. 1172 (81.62%) pts were initially diagnosed at county-level hospitals, among them, 81 (6.91%) pts were subsequently referred to higher-level hospitals. 58 out of 81 pts were referred out primarily to receive breast surgery (71.60%), and most of them were eventually referred back to county-level hospitals to receive adjuvant systemic treatment (94.83%, 55/58). Among 264 pts who were initially diagnosed at higher-level hospitals, a significant portion (84.09%) were referred to county-level hospitals to receive adjuvant systemic treatment. The majority (75.99%, 1092/1436) underwent the entire process of diagnosis and treatment within the county-level hospitals without requiring referral-out, however. Among 341 pts who received treatment at higher-level hospitals, 153 (44.87%) brought back their treatment plan to county-level hospitals, and the majority (90.20%, 138/153) adhered to that treatment plan. Interestingly, pts with higher education levels, and employee medical insurance were more inclined to seek treatment at higher-level hospitals, primarily to recieve breast surgery and neoadjuvant treatment.
Conclusions
Most of the patients admitted to county-level hospitals in China underwent the entire process of diagnosis and treatment within these hospitals, indicated that further efforts to provide high quality, guideline centric care should be concentrated at county-level hospitals.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract